CR20150442A - Cabazitaxel y su uso para el tratamiento de los cánceres de próstata metastásicos - Google Patents

Cabazitaxel y su uso para el tratamiento de los cánceres de próstata metastásicos

Info

Publication number: CR20150442A
Authority: CR; Costa Rica
Prior art keywords: treatment; prostate cancer; metastastic; cabazitaxel; resistant
Prior art date: 2013-03-04

Application number

CR20150442A

Other languages

English (en)

Spanish (es)

Inventor

Steven Neibart

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-04

Filing date

2015-08-25

Publication date

2015-10-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47901920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150442(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-08-25 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2015-10-07 Publication of CR20150442A publication Critical patent/CR20150442A/es

Links

206010060862 Prostate cancer Diseases 0.000 title 1
208000000236 Prostatic Neoplasms Diseases 0.000 title 1
BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 title 1
229960001573 cabazitaxel Drugs 0.000 title 1
230000001394 metastastic effect Effects 0.000 title 1
208000007882 Gastritis Diseases 0.000 abstract 1
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 abstract 1
206010018001 Gastrointestinal perforation Diseases 0.000 abstract 1
208000003011 Neutropenic Enterocolitis Diseases 0.000 abstract 1
206010062959 Neutropenic colitis Diseases 0.000 abstract 1
206010036909 Prostate cancer metastatic Diseases 0.000 abstract 1
206010009887 colitis Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000010227 enterocolitis Diseases 0.000 abstract 1
208000030304 gastrointestinal bleeding Diseases 0.000 abstract 1
230000003054 hormonal effect Effects 0.000 abstract 1
210000003405 ileum Anatomy 0.000 abstract 1
208000003243 intestinal obstruction Diseases 0.000 abstract 1
208000010658 metastatic prostate carcinoma Diseases 0.000 abstract 1
229960005205 prednisolone Drugs 0.000 abstract 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 1
229960004618 prednisone Drugs 0.000 abstract 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CR20150442A 2013-03-04 2015-08-25 Cabazitaxel y su uso para el tratamiento de los cánceres de próstata metastásicos CR20150442A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP13305243		2013-03-04
PCT/EP2014/054156 WO2014135524A1 (fr)	2013-03-04	2014-03-04	Cabazitaxel et son utilisation pour le traitement des cancers de la prostate métastatiques

Publications (1)

Publication Number	Publication Date
CR20150442A true CR20150442A (es)	2015-10-07

Family

ID=47901920

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR20150442A CR20150442A (es)	2013-03-04	2015-08-25	Cabazitaxel y su uso para el tratamiento de los cánceres de próstata metastásicos

Country Status (21)

Country	Link
US (2)	US20150374717A1 (fr)
EP (1)	EP2964212A1 (fr)
JP (1)	JP2016516673A (fr)
KR (1)	KR20150123892A (fr)
CN (2)	CN105073104A (fr)
AU (1)	AU2014224705A1 (fr)
BR (1)	BR112015021450A2 (fr)
CA (1)	CA2903132A1 (fr)
CL (1)	CL2015002454A1 (fr)
CR (1)	CR20150442A (fr)
EA (1)	EA201591622A1 (fr)
HK (1)	HK1215535A1 (fr)
IL (1)	IL241015A0 (fr)
MA (1)	MA38356A1 (fr)
MX (1)	MX2015011589A (fr)
PH (1)	PH12015501900A1 (fr)
SG (1)	SG11201506803XA (fr)
TN (1)	TN2015000378A1 (fr)
TW (2)	TW201438714A (fr)
WO (1)	WO2014135524A1 (fr)
ZA (1)	ZA201506310B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016113752A2 (fr) *	2015-01-12	2016-07-21	Emcure Pharmaceuticals Limited	Formulation liquide de cabazitaxel
WO2022067185A1 (fr) *	2020-09-27	2022-03-31	Veru Inc.	Méthodes de traitement du cancer de la prostate à effets secondaires minimes
JP2024534805A (ja) *	2021-08-17	2024-09-26	フォンダツィオーネペルリスティトゥートオンコロジコディリチェルカ（イオエッレ）	共生細菌は前立腺がんにおいてアンドロゲン生合成を介して内分泌抵抗性を促進する
KR102685052B1 (ko) *	2023-02-15	2024-07-12	사회복지법인 삼성생명공익재단	전이성 전립선암의 호르몬 치료 저항성 예측용 신규 바이오마커 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2862340T3 (es) *	2009-10-29	2021-10-07	Sanofi Mature Ip	Nuevo uso antitumoral de cabazitaxel

2014
- 2014-02-27 TW TW103106902A patent/TW201438714A/zh unknown
- 2014-02-27 TW TW107107732A patent/TW201827417A/zh unknown
- 2014-03-04 CA CA2903132A patent/CA2903132A1/fr not_active Abandoned
- 2014-03-04 SG SG11201506803XA patent/SG11201506803XA/en unknown
- 2014-03-04 KR KR1020157026716A patent/KR20150123892A/ko not_active Withdrawn
- 2014-03-04 HK HK16103503.6A patent/HK1215535A1/zh unknown
- 2014-03-04 EA EA201591622A patent/EA201591622A1/ru unknown
- 2014-03-04 MA MA38356A patent/MA38356A1/fr unknown
- 2014-03-04 JP JP2015560660A patent/JP2016516673A/ja not_active Ceased
- 2014-03-04 CN CN201480012665.2A patent/CN105073104A/zh active Pending
- 2014-03-04 EP EP14708014.7A patent/EP2964212A1/fr not_active Withdrawn
- 2014-03-04 BR BR112015021450A patent/BR112015021450A2/pt not_active IP Right Cessation
- 2014-03-04 WO PCT/EP2014/054156 patent/WO2014135524A1/fr not_active Ceased
- 2014-03-04 CN CN201810410731.1A patent/CN108354921A/zh active Pending
- 2014-03-04 AU AU2014224705A patent/AU2014224705A1/en not_active Abandoned
- 2014-03-04 MX MX2015011589A patent/MX2015011589A/es unknown
2015
- 2015-08-25 CR CR20150442A patent/CR20150442A/es unknown
- 2015-08-27 ZA ZA2015/06310A patent/ZA201506310B/en unknown
- 2015-08-27 PH PH12015501900A patent/PH12015501900A1/en unknown
- 2015-08-31 TN TN2015000378A patent/TN2015000378A1/en unknown
- 2015-09-01 IL IL241015A patent/IL241015A0/en unknown
- 2015-09-02 CL CL2015002454A patent/CL2015002454A1/es unknown
- 2015-09-03 US US14/844,480 patent/US20150374717A1/en not_active Abandoned
2016
- 2016-12-14 US US15/378,728 patent/US20180042941A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20150374717A1 (en)	2015-12-31
PH12015501900A1 (en)	2016-01-11
CN108354921A (zh)	2018-08-03
TW201438714A (zh)	2014-10-16
KR20150123892A (ko)	2015-11-04
MX2015011589A (es)	2016-06-24
HK1215535A1 (zh)	2016-09-02
ZA201506310B (en)	2017-02-22
CA2903132A1 (fr)	2014-09-12
EP2964212A1 (fr)	2016-01-13
CL2015002454A1 (es)	2016-02-12
TN2015000378A1 (en)	2017-01-03
BR112015021450A2 (pt)	2017-07-18
US20180042941A1 (en)	2018-02-15
TW201827417A (zh)	2018-08-01
JP2016516673A (ja)	2016-06-09
MA38356A1 (fr)	2017-06-30
WO2014135524A1 (fr)	2014-09-12
IL241015A0 (en)	2015-11-30
SG11201506803XA (en)	2015-09-29
AU2014224705A1 (en)	2015-09-24
CN105073104A (zh)	2015-11-18
EA201591622A1 (ru)	2016-04-29

Publication	Publication Date	Title
MX2012005030A (es)	2012-12-05	Nuevo uso antitumoral de cabazitaxel.
GT201200220A (es)	2014-12-22	Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
CR20150483A (es)	2015-11-02	Composiciones y métodos para el diagnóstico y tratamiento del cáncer hepático
MX2016002137A (es)	2017-02-15	Ciertas entidades quimicas, composiciones y metodos.
MX2018011992A (es)	2019-01-24	Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
CL2017000310A1 (es)	2017-08-18	Anticuerpos anti tigit
CL2017001171A1 (es)	2017-09-15	Peptidos macrocíclicos útiles como inmunomoduladores
CL2016003350A1 (es)	2018-05-11	Inhibidores de demetilasa-1 especifica de lisina
MX2016002544A (es)	2016-06-17	Compuestos utiles como inmunomoduladores.
MX2016013239A (es)	2017-05-03	Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19.
CR20120202A (es)	2012-06-12	Métodos y composiciones para tratar cáncer
MX2018005061A (es)	2019-02-28	Compuestos de interacción con glicanos y métodos de uso.
BR112017027954A2 (pt)	2018-08-28	métodos de tratamento de tumores de célula epitelioide
MX385842B (es)	2025-03-18	Conjugados de partículas de tipo virus y uso de las mismas.
MX2016014555A (es)	2017-05-30	Composiciones novedosas, usos y metodos para hacerlas.
ECSP14014778A (es)	2016-01-29	Composiciones derivadas de la quitosana
BR112016017112A2 (pt)	2017-08-08	Composições de apilimod e métodos de uso das mesmas
CO2017001226A2 (es)	2017-05-10	Derivados de 6–alquinil–piridina como miméticos de smac
CR20150496A (es)	2016-02-19	Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
MX391474B (es)	2025-03-21	Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
CR20150442A (es)	2015-10-07	Cabazitaxel y su uso para el tratamiento de los cánceres de próstata metastásicos
EP3548088A4 (fr)	2020-07-22	Thérapie pour le cancer urothélial métastatique avec le conjugué anticorps-médicament, sacituzumab govitécan (immu-132)
MX2016016507A (es)	2017-04-27	Composiciones y metodos para tratar canceres.
MX2018001315A (es)	2018-08-15	Inhibidores de fucosidasa.
MX2017014463A (es)	2018-03-21	Cabazitaxel y su uso para tratar cancer.